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SUMMAry
A retrospective chart review was used for 31 patients with sudden, progressive or fluctuating sensorineural hearing loss (Shl) in the only 
hearing ear who had been consecutively evaluated at the EnT, Audiology and Phoniatrics Unit of the University of Pisa. The group of 
patients was evaluated with a complete history review, clinical evaluation, imaging exam (Mri, CT), audiologic tests (tone and speech au-
diometry, tympanometry, study of stapedial reflexes, ABr and otoacoustic emission) evaluation. in order to exclude genetic causes, patients 
were screened for CX 26 and CX30 mutations and for mitochondrial dnA mutation A1555g. Patients with sudden or rapidly progressive 
Shl in the only hearing ear were treated with osmotic diuretics and corticosteroids. in patients who did not respond to intravenous therapy 
we performed intratympanic injections of corticosteroid. hearing aids were fitted when indicated and patients who developed severe to 
profound Shl were scheduled for cochlear implant surgery. The aim of this study is to report and discuss the epidemiology, aetiopathogen-
esis, therapy and clinical characteristic of patients affected by Shl in the only hearing hear and to discuss the issues related to the cochlear 
implant procedure in some of these patients, with regard to indications, choice of the ear to implant and results.
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riASSUnTo 
Uno studio retrospettivo è stato condotto su 31 pazienti, giunti all’osservazione della cinica ORL Audiologia e Foniatria dell’Università 
di Pisa dal 2007 al 2013, affetti da ipoacusia neurosensoriale improvvisa, fluttuante o progressiva nell’unico orecchio udente. L’intero 
gruppo di pazienti è stato valutato con una adeguata anamnesi, otomicroscopia, esami di imaging (TC RMN), test audiologici (audiome-
tria tonale e vocale, impedenziometria, potenziali evocati uditivi e otoemissioni acustiche). Questo gruppo di pazienti è stato sottoposto 
anche a una valutazione genetica (ricerca mutazioni CX 26, CX 30 e DNA mitocondriale A1555G) e a test di laboratorio. I pazienti con 
ipoacusia improvvisa o rapidamente progressiva sono stati trattati con diuretici osmotici e corticosteroidi (endovena o intratimpanici). I 
pazienti che non hanno recuperato in maniera adeguata dopo il trattamento sono stati avviati a un percorso di protesizzazione. Nei pazienti 
con insufficiente resa protesica sono stati sottoposti ad impianto cocleare. Lo scopo di questo studio è quello di discutere l’epidemiologia, 
l’eziopatogenesi e le caratteristiche cliniche di pazienti affetti da ipoacusia neurosensoriale nell’unico orecchio udente e inoltre discutere 
le indicazioni e la scelta dell’orecchio da impiantare in questa categoria di pazienti. 
PArolE ChiAVE: Ipoacusia neurosensoriale • Unico orecchio udente • Ipoacusia progressiva • Impianto cocleare
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Introduction
Patients suffering from severe to profound unilateral senso-
rineural hearing loss (Shl) in one ear can develop idiopath-
ic Shl in the contralateral ear after a period varying from 
months to years. This condition may be sudden, progressive 
or fluctuating. The development of Shl is a dramatic event 
leading patients with an only hearing ear to be confused, 
worried, anxious and isolated from the surrounding world, 
and thus worthy of special consideration. This small sub-
population of patients becomes practically deaf, so that Shl 
in the only hearing ear is an audiologic emergency. So far, it 
has not been possible to provide any specific therapy, while 
steroids, vasodilators and diuretics are frequently prescribed. 
Cochlear implants are often the last resort to rehabilitate 
these patients when medical therapy and hearing aids do 
not result in satisfactory hearing performance. 
We believe it is of interest to investigate the clinical char-
acteristics of this specific group of patients because the 
scientific literature describing this “disease” is relatively 
limited. To our knowledge, the aetiopathogenesis and in-
cidence of this clinical condition have never been previ-
ously reported. There are only a few studies reporting on 
sudden Shl 1-4 in the only hearing ear, but none describ-
ing the progressive forms of the disease. 
in this regard, delayed endolymphatic hydrops (dEh) is 
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a clinical entity that may present with features similar to 
Shl in the only hearing ear. This disease, first reported by 
nadol et al. in 1975 5, is characterised by the early onset 
of profound or total Shl in one ear. After a prolonged 
period of stagnation, a late phase of the disease appears 
with different otologic symptoms that can be described 
as two main types of dEh: ipsilateral and contralateral 
variants. ipsilateral dEh appears with episodic vertigo in 
the deaf ear, while contralateral dEh appears as fluctuat-
ing hearing loss and/or episodic vertigo in the previously 
normal ear. in contralateral dEh, the Shl first affects the 
low-tone frequencies and is always fluctuating 6.
in this paper, we report on a retrospective case series of 
34 patients (collected over 6 years) with one deafened 
ear – as a result of various causes – who subsequently 
developed progressive, fluctuating or sudden Shl in the 
contralateral ear. The aim is to present and discuss epide-
miology, aetiopathogenesis and clinical characteristics of 
patients affected by Shl in the only hearing hear and to 
discuss the issues related to the cochlear implant proce-
dure in these patients with regards to indications, choice 
of the ear to implant and results.
Materials and methods
A retrospective chart review was used for 34 patients with 
Shl in the only hearing ear who had been consecutively 
evaluated at the Ear, nose and Throat (EnT) Audiology 
and Phoniatrics Unit of the University of Pisa (tertiary 
referral centre for audiological disease) between January 
2007 and January 2013. The sample was composed of 
19 men and 15 women. All data were collected after re-
ceiving informed consent by all patients involved and ac-
cording to the declaration of helsinki. All patients were 
evaluated with a complete history review (with particular 
attention to family history and other systemic diseases). 
Patients underwent otomicroscopy, pure tone audiometry, 
speech audiometry, tympanometry and study of stapedial 
reflexes. All patients were also evaluated with auditory 
brainstem responses and otoacoustic emissions. Patients 
who complained of dizziness underwent vestibular ex-
amination with videonystagmography. 
Several blood tests were carried out to exclude any known 
cause of hearing loss (complete blood cell count, general 
chemistry screen, VES, PCr, mucoproteins, fibrinogen, 
urine test, total and fractionated protein, bilirubin, νgT, 
ldh, SgoT, SgPT, CPK, TSh, T3, T4, serological tests 
for toxoplasmosis, syphilis, borrelia burgdorferi, antibod-
ies AnA EnA, AMA, ASMA, CliF test, AnCA). in or-
der to exclude genetic causes, patients were screened for 
connexin 26 and connexin 30 mutations and for the most 
frequent mitochondrial dnA mutation related to deafness 
(A1555g). Patients were also evaluated with 1.5-3.0 Tesla 
contrast-enhanced magnetic resonance imaging (Mri) of 
the brain, cerebellopontine angle and inner ear. The study 
protocol of the inner ear includes a thin slice heavily T2W 
3d sequence (FiESTA) to stress the signal difference 
between the cerebrospinal fluid (CSF) and other tissues, 
and thin axial and coronal SE or FSE 2d T1W with and 
without gadolinium administration. Axial FlAir imag-
ing was performed, which covered the entire brain. All 
patients underwent CT scan of petrous bone to exclude 
advanced otosclerosis, perilymphatic fistulas or other 
bone pathologies. Patients with a history of hypertension 
or cardiovascular disease were also evaluated with colour 
doppler ultrasound of neck vessels. 
Patients with known autoimmune diseases, vascular dis-
eases, diabetes and other metabolic systemic diseases 
were excluded. 
out of 34 patients three were excluded: one because of the 
presence of a mutation in the connexin 26 gene (M34T), 
another for an enlarged bilateral vestibular aqueduct 
(EVA) and one because of the presence of superficial he-
mosiderosis of the central nervous system. This patient 
experienced unilateral profound deafness after a head 
trauma with a temporal bone fracture and some years later 
developed fluctuating progressive Shl in the contralat-
eral ear 7. 
in 18 of the 31 patients included, the aetiology of Shl 
in the first deafened ear was unknown and was defined 
as idiopathic; in 6 patients Shl was due to ear surgery 
(1 patient with translabyrinthine surgery for acoustic neu-
roma; in 5 patients deafness was due to tympanoplasty for 
cholesteatoma or middle ear chronic otitis with postop-
erative severe or profound Shl). in another patient Shl 
was subsequent to a head trauma with a temporal bone 
fracture. An infectious aetiopathogenesis (bacterial men-
ingitis, acute otitis media, systemic viral infection etc.) 
was recognised in another 6 cases.
idiopathic Shl occurring in the second affected ear was 
classified as follows:
• progressive: Shl ≥15 dB hl (PTA at 0.5-1-2-4 khz) 
occurring in a 10-year period 8;
• sudden: abrupt hearing deterioration of ≥30 dB hl in 
at least 3 consecutive frequencies occurring in a period 
no longer than 3 days 9;
• progressive-fluctuating: recurrent episodes of Shl of 
any entity that recover rapidly. 
The entire group of patients was evaluated by the same 
audiological team and submitted to the battery of audio-
logical tests that we routinely use to evaluate patients with 
progressive, fluctuating or sudden Shl (Table i). 
Patients with sudden or rapidly progressive Shl in the 
only hearing ear were treated with glycerol 10% 500 ml/
day i.v. for 7 days, methylprednisolone 250 mg/day for 3 
days, and then tapered for a 15-day period and a proton 
pump inhibitor (lansoprazole 30 mg/die) was added. in 
patients who did not respond to intravenous therapy we 
performed intratympanic injections of dexamethasone (4 
mg/ml 3 injections for 10 days). hearing aids were fitted 
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when indicated and patients who developed severe to pro-
found Shl were scheduled for cochlear implant surgery. 
Results
The mean age of patients when Shl occurred in the first 
ear was 28.09 years (age range 0-62 years). The mean 
pure tone average (PTA between 0.5 khz and 1 khz, and 
2 khz) in the first deafened ear was 82.03 dB (range 70 
dB-120dB). Shl occurred in the contralateral ear after a 
mean period of 25.09 years (age range 2-57 years). The 
onset of Shl in the contralateral ear was sudden in 12 pa-
tients, progressive in 13 cases and progressive with fluc-
tuations in another 6 cases.
With regards to the hearing threshold curve in the second 
affected ear, 18 patients developed downsloping Shl, 4 
patients upsloping Shl and the last 9 patients a flat curve 
Shl. The mean mean pure tone audiometry (PTA) in the 
second ear that developed a hearing loss was 42.03 dB 
(range 30-120 dB) (Table ii). 
Eleven of 31 patients complained monolateral tinnitus 
(only in the first ear interested by Shl), while 20 of 31 
complained of bilateral tinnitus. Four of 31 patients com-
plained of occasional and non-recurrent vertigo, not tem-
porally related to the development of Shl. 
of the 18 patients with sudden or rapidly progressive Shl 
in the second ear, 5 (# 1, 7, 18, 25, 26) were treated with 
the above-mentioned mentioned protocol; the remaining 
13 patients referred to our clinic over 6 months after the 
onset of Shl and with no indications to medical treat-
ment. in these patients, the mean PTA before therapy was 
59.6 dB and 47.6 dB after therapy with a mean improve-
ment of 12.0 dB.
hearing aids fitting in the best hearing ear, or bilaterally 
when indicated, was proposed to 25 of 31 patients. in 17 
of 25 patients, hearing performance were good: mean 
open-set speech-recognition score in silence was 78.8% 
(range 60-100%). While in 8 of 25 patients (# 3, 8, 11, 27, 
28, 29, 30, 31) the hearing performance with hearing aids 
was very poor (mean open-set speech-recognition score in 
silence 25.6%, range 0-45%), and cochlear implant sur-
gery was proposed. Patients 3 and 11 declined the cochle-
ar implant (Ci) procedure. The remaining 6 patients were 
implanted by using a nucleus Contour Advance Ci24rE 
(Cochlear) (Table iii). of a group of 184 patients (both 
children and adults), 6 were implanted in the same period 
(2007-2013). All patients were operated by the same sur-
gical team and the final insertion of the Ci was performed 
by the same senior surgeon. The array of electrodes was 
fully inserted in all cases. A post-operative X-ray of the 
skull was performed to confirm the correct placement of 
the implant. Five of six patients were implanted in the sec-
ond deafened ear, while one patient (# 8) was implanted 
in the first deafened ear. The mean preoperative open-
set speech-recognition score in silence was 20% (range 
0-40%). The mean post-operative score (Table iii), meas-
ured 1 year after the switch-on of the implant, was 83% 
(range 70-100%) with a significant improvement in hear-
ing performance. 
Discussion
Epidemiology
To our knowledge, there are no papers in the literature re-
porting epidemiologic data of idiopathic Shl in the only 
hearing ear. 
Few reports 1 2 10 11 on sudden Shl in the only hearing ear 
have been published. Stahl and Cohen 2 reported that 20% 
of patients with sudden Shl were deaf in the contralateral 
ear (9 of 45 patients), while lee et al. 1 reported a percent-
age of 11.5% (25 out of 217 patients). Fetterman et al. 12 
found that 1.7% of patients (14/823 patients) with sud-
den Shl had bilateral loss. Shaia and Sheehy 11 reported 
1,220 cases of sudden Shl observed at the house Ear 
Clinic from 1964 to 1972, 4% of which were bilateral. 
half of their cases occurred simultaneously while the oth-
ers were sequential. Therefore, the occurrence of sudden 
Shl seems to be a rather common event in patients with 
only one hearing ear, and more frequent than sudden Shl 
in the normal population, which is reported to be 5 to 160 
per 100,000 13-14. Concerning the involvement of the only 
hearing ear, patients with progressive or fluctuating Shl 
(19/31 or 61% in our sample) should be added to patients 
Table I. Protocol of clinical evaluation for SHL in the only hearing ear.
Auditory test Tonal and speech audiometry
Tympanometry study of stapedial reflex
ABR and otoacustic emission
Auditory skills test
Laboratory test Blood count
Glucose, cholesterol, triglycerides
Creatinine, blood urea nitrogen, electrolytes
Total protein and fractionated
Bilirubin, νGT, LDH, SGOT, SGPT, CPK
TSH, T3, T4
Urine test
Serological tests for toxoplasmosis, syphilis, 
Borrelia burgdorferi
ESR, CRP, mucoproteins, fibrinogen
Antibodies: ANA, ENA, AMA, ASMA, CLIF test 
ANCA, anti-collagen type II, antiphospholipids
Genetic test Mutation of CX 26 and 30
Mitochondrial DNA (A1555G)
Imaging test 3.0 Tesla MRI 
CT
Colour Doppler of neck vessels
Specialist evaluation Neurological 
Rheumatologic
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Table II. Patients and clinical characteristics.
Age Age of 
first 
SHL
Aetiology 
first 
SHL
Age SHL 
contralateral 
ear
PTA 
first 
ear
PTA 
second 
ear
Development 
SHL in the second ear
Audiometric curve
1 45 18 Idiopathic 42 73 80 Sudden Downsloping
2 50 28 Idiopathic 50 78.3 60 Fluctuating Downsloping
3 76 61 Surgery for neuroma 63 120 80 Progressive Downsloping
4 32 5 Infective 30 120 70 Fluctuating Downsloping
5 62 38 Idiopathic 52 87 90 Progressive Downsloping
6 70 60 Idiopathic 69 70 30 Progressive Upsloping
7 69 55 Infective (OMC) 57 120 50 Sudden Downsloping
8 57 41 Idiopathic 52 120 80 Progressive Downsloping
9 36 15 Idiopathic 34 120 32.5 Fluctuating Upsloping
10 75 14 Surgery for OMC 65 95 65 Progressive Downsloping
11 75 14 Trauma 65 120 100 Progressive Pantonal
12 60 5 Infective 60 70 57 Sudden Downsloping
13 72 62 Surgery for OMC 72 73 63 Sudden Downsloping
14 66 9 Infective 65 120 50 Progressive Upsloping
15 72 33 Surgery for OMC 70 110 45 Progressive Downsloping
16 71 47 Surgery for OMC 52 90 86.25 Progressive Pantonal
17 61 6 Surgery for OMC 54 120 47.5 Fluctuating Downsloping
18 53 1 Infective 38 112.5 40 Sudden Downsloping
19 64 62 Idiopathic 64 82.5 70 Sudden Downsloping
20 45 1 Idiopathic 38 120 58.75 Sudden Downsloping
21 65 48 Idiopathic 57 120 77.5 Sudden Downsloping
22 29 2 Infective 16 120 35 Sudden Upsloping
23 22 0 Idiopathic 21 120 46.7 Progressive Pantonal
24 58 4 Idiopathic 29 116.7 50 Progressive Pantonal
25 68 48 Idiopathic 63 90 35 Fluctuating Pantonal
26 44 0 Idiopathic 42 105 33 Fluctuating Downsloping
27 74 14 Idiopathic 71 120 73.3 Sudden Downsloping
28 65 60 Idiopathic 65 81.6 120 Sudden Pantonal
29 69 40 Idiopathic 66 120 78.3 Progressive Pantonal
30 70 60 Idiopathic 69 113.3 76.6 Sudden Pantonal
31 65 20 Idiopathic 58 98.3 101.6 Progressive Pantonal
32 52 20 M34T 41 115 45 Progressive Pantonal
33 45 6 EVA 15 80 40 Fluctuating Pantonal
34 75 50 Trauma _ SS 70 120 52.5 Progressive Downsloping
Table III. Patient who underwent a CI procedure.
Patient n Ear implanted:
1st ear or 2nd ear
Auditory skills test 
recognition open-set 
bisyllabic word in silence
Use of bimodal 
hearing stimulation
Time from onset of 
HL in the implanted 
ear 
Use of hearing aid in the 
ear implanted before 
surgery
8 1st 70% (100% IC+HA) Yes 16 years Yes (for 5 years)
27 2nd 85% No 3 years Yes (for 2 years)
28 2nd 80% Yes 3 months No
29 2nd 75% No 3 years Yes (for 1 year) 
30 2nd 100% No 2 months No
31 2nd 90% No 6 years Yes (for 4 years)
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affected by sudden Snhl. This has led us to think that the 
development of Shl in the two ears is not an independ-
ent event, but that it could be related to aetiopathogenetic 
factors. 
We believe that the possibility of developing Shl in the 
only hearing ear is not a negligible fact and that further 
epidemiologic studies should be conducted in this par-
ticular group of patients to better understand the risks for 
patients with an only hearing ear to develop Shl in the 
contralateral ear. 
Aetiology
The aetiological study of hearing loss is greatly important 
for both comprehensive treatment of disease and progno-
sis. The aetiology of this condition has been the subject of 
numerous reports in the literature, but to our knowledge 
no data are available concerning the aetiology of hearing 
loss in patients with an only hearing ear. in the past years 
our group has made a great effort to investigate the aetiol-
ogy of hearing loss, in particular of progressive Shl and, 
as previously described 8, we have defined the following 
causes: genetic mutations, inner ear malformations, infec-
tious diseases, autoimmune disease, neoplastic, trauma, 
etc. Patients with hearing loss, especially those with an 
only hearing ear should be submitted to accurate and 
comprehensive aetiologic evaluation to investigate a pos-
sible correlation between the aetiology and the risk of de-
veloping a contralateral Shl.
despite the comprehensive aetiological study in our pa-
tients, the aetiology of Shl in the only hearing ear re-
mains unknown in a high percentage of these patients 
(31/34 patients, 91%). Therefore, we defined the disease 
as idiopathic and can only make some hypotheses on its 
origins. 
A first hypothesis is genetic: unknown genetic mutations 
might lead to the development of Shl, possibly with a 
time lapse between the two ears. 
A second hypothesis is the presence of microscopic osse-
ous or membranous labyrinth malformations that are not 
visible at the resolution of our diagnostic tools. The most 
recent imaging techniques have revealed inner ear mal-
formations in a relevant percentage of patients affected 
by Shl. The data, reported in the scientific literature, 
mainly concern the paediatric population with a reported 
prevalence of inner ear malformations in children with 
profound Shl between 14-30% 15. however, minor mal-
formations or malformations limited to the membranous 
labyrinth, not detectable with common diagnostic tools, 
may be responsible for some cases of Shl of unknown 
origin. 
A third hypothesis is the viral one. Some authors have 
hypothesised two different possibilities in the develop-
ment of Shl by viral damage. Schuknecht et al.  16 ex-
plained the genesis of dEh, and hypothesised a praecox 
viral labyrinthopathy leading to early cochleo-vestibular 
damage in one ear with subsequent delayed hydrops in 
the contralateral ear due to an alteration of endolymph 
production and resorption. other authors 17 have consid-
ered that a praecox viral infection could be responsible for 
Shl in the first ear and then a delayed reactivation of the 
same virus could cause Shl in the second ear. They found 
the genome cytomegalovirus (CMV) within the cochlea 
of a deaf patient with no evidence of acute infection. The 
presence of this virus suggested a possible role in inner 
ear injury through reactivation of the latent virus within 
the cochlea. 
A final possible hypothesis is the autoimmune one. To 
explain the genesis of dEh, our group  18 hypothesised 
that contralateral hydrops could be mediated by an auto-
immune process. We found an non-specific immunologi-
cal pattern that was altered in 50% of patients with dEh 
and was significantly higher than in patients affected by 
Ménière’s disease. A similar hypothesis is that Shl in 
the contralateral ear may be caused by an autoimmune 
mechanism involving recirculating memory cells sensi-
tised against cochlear tissues. A comparable mechanism 
is described in ophthalmology, which is called sympathet-
ic ophthalmia 19 in which there is an inflammatory reac-
tion in the healthy eye after a traumatic destruction of the 
other eye. The pathologic mechanism could be explained 
as follows: during an infection, trauma, or surgery there 
is exposure of anatomically sequestered proteins of the 
inner ear. These proteins, recognised as ‘foreign’, serve 
as antigens, and result in the induction of lymphocytes. 
These cells re-circulate as memory cells and reach the 
intact contralateral cochlea, thus leading to immune re-
sponse and damage of the organ. in 1994, gloddek et al. 20 
described an animal model of this “sympathetic cochleo-
labyrinthitis”. They found a high percentage of sensitised 
lymphocytes on the apical turn of the cochlea that is not 
in agreement with the clinical findings herein, since the 
patients examined in this study (18/31) mainly showed a 
downsloping audiometric curve. 
Clinical issues and therapies
in reviewing the literature, we found a number of studies 
reporting patients with sudden Shl in the only hearing 
ear and describing their clinical features, treatment and 
results (Table iV) 1-4. The samples 1-4  (Table iV) were het-
erogeneous and the therapy protocols were different, so 
that it was difficult to compare the results and efficacy of 
the therapies. 
in 2006, Stahl and Cohen  2 reported 9 cases of patients 
affected by sudden Shl in the only hearing ear, and de-
scribed the clinical characteristics of patients and features 
of the hearing threshold curve. The authors treated pa-
tients with prednisolone 60-80 mg/day, who achieved a 
mean improvement of 9 ± 8.7 dB in the three main affect-
ed frequencies. Stahl and Cohen 2 concluded that patients 
affected by a sudden Shl in the only hearing ear might 
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receive the same treatment with corticosteroids as other 
patients affected by sudden Shl. 
Pykko et al. 4 reported on 10 cases of patients, 6 of whom 
were affected by Mènière’s disease, one by Cogan’s syn-
drome and 3 by idiopathic Shl; they treated patients with 
corticosteroids and immunosuppressants, and hypoth-
esised an autoimmune genesis of Shl in the contralateral 
ear. Patients were treated with azathioprine (25 mg tid) 
and prednisolone (5-15 mg/day) after an initial dose of 
20-40 mg and reported a mean improvement of 22.4 dB. 
lee et al. 1 disposed of a larger case series of 24 patients 
and were the only authors reporting on patients who had 
undergone cochlear implantation. They treated patients 
with prednisolone 1-1.15 mg/kg/day tapered, MgSo4 
(4 g/day), dextran (10 ml/kg in 5% dextrose), Carbogen 
inhalation and corticosteroid intratympanic injection if 
there was no improvement. A recovery rate of 64% was 
reported. 
We treated our group of patients with the following thera-
peutic protocol: glycerol 10% 500 ml/day i.v. for 7 days, 
methylprednisolone 250 mg/day for 3 days then tapered 
for a 15-day therapy and a proton pump inhibitor (lan-
soprazole 30 mg/day) 21. Patients who did not respond to 
intravenous therapy after 7 days were submitted to 3 in-
tratympanic injections of dexamethasone (4 mg/ml) in 10 
days.
We treated only 5 (# 1, 7, 18, 25, 26) of 18 patients with 
sudden or rapidly progressive Shl because the remaining 
13 patients had referred to our clinic with a time-lapse 
that was longer than 6 months from the onset of Shl in 
the second ear, and there were no indications about medi-
cal treatment. Mean PTA improvement in treated patients 
was 12.0 dB [range 0-24 dB]. These results are similar to 
those found by other authors 2.
The treatment of sudden idiopathic Shl is debated in the 
literature and there is currently no evidence of its efficacy. 
recent clinical guidelines  22 suggest to use only corti-
costeroids (oral, iv, or intratympanic) as first line therapy 
and eventually hyperbaric oxygen therapy. guidelines 
discourage clinicians from using pharmacologic agents 
(antivirals, thrombolytics, vasodilators, vasoactive sub-
stances, antioxidants) that may have side effects and no 
documented efficacy. The guidelines also recommend 
the use of intratympanic injection of corticosteroids as a 
salvage therapy. in this specific group of patients, we de-
cided to add glycerol to the therapeutic protocol, owing to 
the analogies between idiopathic Shl in the only hearing 
ear and contralateral-type dEh. diuretics significantly 
improve the hearing of patients with this type of dEh 23.
Outcomes of CI procedure in patients with SHL  
in the only hearing ear
Ci is a viable option for patients whose hearing deficit 
becomes bilaterally severe to profound and who no longer 
benefit from hearing aids.
only one paper 1 reported on patients with idiopathic Shl 
in the only hearing ear that underwent a Ci procedure. Six 
of 25 patients were submitted to Ci; the results in terms of 
reaching the top of the category of auditory performances 
(CAP) defined as ‘use of telephone with known speaker’ 
were good. All these patients were implanted in the sec-
ond ear that developed Shl. The time necessary to reach 
CAP was linked to the time of auditory deprivation in the 
second ear. The authors concluded that a treatment like 
Ci might be considered as early as 3 months so that the 
patient can return to daily verbal communication. 
in our group, 6 of 31 patients underwent a Ci procedure; 
5 of 6 were implanted in the second ear that developed 
Shl, and consequently with a shorter deprivation. The 
hearing performances were very good in all these patients 
with a mean of 87.5% [range 75-100%] of post-operative-
ly disyllabic word recognition scores. 
Table IV. Studies reporting patients with sudden SHL in the only hearing ear.
Article Year Patients Aetiology of 
1st ear HL
Development of 
2nd ear HL
Type of 
audiometric curve 
in the 2nd ear
Treatment Cochlear 
implant
Stahl and 
Cohen
2006 9 - Sudden 4 Downsloping
5 Upsloping
Prednisolone 60-80 
mg/day
-
Lee et al. 2010 25 12 idiopathic
7 Inflammatory
2 Trauma
1 Acoustic 
Schwannoma
2 AVL
Sudden - Prednisolone  1-1.15 
mg/kg/day tapered
MgSO
4 
(4 g/day)
Dextran (10 ml/kg in 
5% dextrose)
Carbogen Inhalation
Intratympanic injection 
if no recovery
6
Hawkings 2008 1 Congenital Sudden Pantonal Oral steroids -
Pykko et al. 1997 10 6 Ménière
1 Cogan
3 Idiopathic
2 Sudden
1 Fluctuating
7 Progressive
- Azathioprine (25 mg tid)
Prednisolone (5-15 mg/
day) after initial dose of 
20-40 mg
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only one patient was implanted in the first ear that devel-
oped Shl. This choice was due to the fact that the hearing 
threshold was significantly better in the second deafened 
ear (so as to allow the use of a hearing aid, even if with 
partial results), and also to the fact that the first ear had a 
history of slight progressive Shl with long term use of a 
hearing aid. The auditory performances with Ci only were 
good and satisfactory even in this patient, but lower than 
in the previously reported 6 patients (70% recognition of 
bisyllabic words). however, with bimodal stimulation the 
patient reached 100% of the recognition score. Moreover, 
he reported good satisfaction with the implant and ben-
efits in the quality of life.
in patients with bilateral severe to profound Shl, can-
didates for a Ci procedure, the criteria employed for the 
choice of the ear to implant has changed over the years. 
if residual hearing in one ear is suitable for hearing aid 
fitting, implantation in the worse ear is preferred to al-
low bimodal stimulation. if none of the ears is good for 
hA fitting, it is usually recommended to implant the ear 
with less hearing deprivation. hearing deprivation is one 
of the stronger predictors of Ci outcome in adults with 
post-verbal hearing loss. 
however, in the literature there is no clear agreement on 
the choice of the side to implant in patients with monoau-
ral sound deprivation. Several authors 24-25 have reported 
that implanting the ear with a longer deprivation did not 
appear to have a negative impact on Ci outcome. notwith-
standing, the UK Cochlear implant Study group 26 argued 
that Ci was less effective in the ear with a longer depriva-
tion even if residual hearing is better. 
recently, Boisvert et al. 2012 27 examined speech recog-
nition results in 30 adults with bilateral Shl using only 
one hearing aid. Fifteen received the implant in the sound-
deprived ear and 15 in the aided ear. The authors con-
cluded that there was no significant difference in speech 
recognition results for the 2 groups when the patient in the 
group with Ci in the sound deprived ear were tested with 
bimodal stimulation.
Among the 6 patients of our sample submitted to Ci, 5 
were not suitable for hA fitting, and the second deafened 
ear was implanted with good results. We decided to im-
plant the remaining one patient on the first deafened ear, 
because the second ear was suitable for hA fitting.
Conclusions
herein, we focus our attention on progressive, sudden or 
fluctuating Shl in the only hearing ear. Shl occurrence 
is not negligible and it would be important to better un-
derstand the risk for patients with an only hearing ear to 
develop Shl in the contralateral one. 
We believe a comprehensive diagnostic protocol is man-
datory to investigate all known causes of hearing loss (ear 
malformations, genetic anomalies, superficial siderosis, 
etc.) and, if possible, to prevent contralateral involvement. 
Further studies should be conducted in the aetiology, epi-
demiology and aetiopathogenesis, because at present only 
hypotheses (genetic, micro-malformation, autoimmune, 
viral) can be made regarding the genesis of Shl in the 
only hearing ear.
hA fitting may not be simple for the progression or fluc-
tuation of hearing loss over time, and therefore Ci may 
be indicated in patients that developed a bilateral severe 
to profound Shl. According to literature data, the results 
of our patients submitted to Ci are satisfactory. our data 
(even if the sample is small) seem to indicate that bet-
ter results can be expected in patients implanted in the 
ear with a shorter deprivation. good results can be also 
achieved in patients implanted in the first deafened ear by 
using bimodal stimulation.
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